Iranian Journal of Allergy, Asthma and Immunology 2014. 13(5):300-306.

Immunopathology of sarcoidosis.
Esmaeil Mortaz, Mohammad Reza Masjedi, Payam Tabarsi, Mihan Pourabdollah, Ian M Adcock


The immunopathology of sarcoidosis remains elusive despite years of research into this multiorgan disease.However, recent studies have provided new insights into the genetics and immune components involved in the clinical manifestation of the disease.
Granulomatous inflammation is due to the host immune response to a persistent poorly degradable unknown antigen.Mycobacterium tuberculosis (MTB) is the major disease driver in many patients.
The  immune  mechanisms  that  cause this  disease start  with  the  antigenic stimulus, followed by T-cell, macrophage and dendritic cell activation via a classic MHC II–mediated pathway.
In addition, the profile of immune mediators reported in sarcoidosis indicates that the inflammasome pathway plays a critical role in disease pathogenesis. Increased understanding of the signal  ransductions pathways involved in the induction of inflammatory processes in sarcoidosis could give rise to new therapeutic approaches in future.


Inflammatory cells; Sarcoidosis; Tuberculosis

Full Text:



1.   Gerke   AK.   Hunninghake   G.   The   Immunology   of Sarcoidosis. Clin Chest Med 2008; 29(3):379–90.

2.   Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at  sites  of  disease  activity.  N  Engl  J   Med  1981;305(8):429–34.

3.   Spagnolo  P,  Grunewald  J.  Recent  advances  in  the genetics of sarcoidosis. J Med Genet. 2013; (5):290-7.

4.  Perez RL, Rivera-Marrero CA, Roman J. Pulmonary granulomatous inflammation: From sarcoidosis to tuberculosis. Semin Respir Infect 2003; 18(1):23–32.

5.   Thomeer M,  Demedts M,  Wuyts W. Epidemiology of sarcoidosis. Eur Respir Mon 2005; 32:13–22.

6.   du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med 2003; 253(1):4–17.

7.   Vidal S,  de  la  Horra C,  Martin J,  Montes-Cano MA, Rodríguez E, Respaldiza N, et al. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect 2006; 12(3):231–5.

8.   Drake WP, Newman LS. Mycobacterial antigens may be important in sarcoidosis pathogenesis. Curr Opin Pulm Med 2006; 12(5):359–63.

9.   Ishige I, Eishi Y, Takemura T, Kobayashi I, Nakata K, Tanaka  I,  et  al.  Propionibacterium acnes  is  the  most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis. Sarcoidosis  Vasc  Diffuse Lung  Dis  2005;22(1):33–42.

10. Oswald-Richter KA,  Drake WP. The  etiologic role of infectious antigens in sarcoidosis pathogenesis. Semin Respir Crit Care Med 2010; 31(4):375–9.

11. Gupta   D,   Agarwal   R,   Aggarwal   AN,   Jindal   SK.Molecular  evidence  for  the  role  of mycobacteria  in sarcoidosis:   a   meta-analysis.   Eur   Respir   J   2007; 30(3):508–16.

12. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336(17):1224-34.

13. Kataria YP, Holter JF. Immunology of sarcoidosis. Clin Chest Med 1997; 18(4):719-39.

14. Barnard   J,   Newman   LS.   Sarcoidosis:   immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 2001; 13(1):84-91.

15. Hayashi Y, Ishii Y, Hata-Suzuki M, Arai R, Chibana K, Takemasa A, et al. Comparative analysis of circulating dendritic cell subsets in patients with atopic diseases and sarcoidosis. Respir Res 2013; 14:29.

16. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2013, S30. pii: S0140-6736(13)60680-7.

17. Oswald-Richter KA,  Drake WP. The  etiologic role of infectious antigens in sarcoidosis pathogenesis. Semin Respir Crit Care Med 2010; 31(4):375-9.

18. Israel-Biet   D,   Valeyre   D.   Diagnosis   of   pulmonary sarcoidosis. Curr Opin Pulm Med 2013; 19(5):510-5.

19. Tazi A, Bouchonnet F, Valeyre D, Cadranel J, Battesti JP, Hance AJ. Characterization of gamma/delta T- lymphocytes  in  the  peripheral  blood  of  patients  with active tuberculosis. A comparison with normal subjects and patients with sarcoidosis. Am Rev Respir Dis 1992;146(5 Pt 1):1216-21.

20. Hirshaut Y, Glade P, Vieira LO, Ainbender E, Dvorak B, Siltzbach LE. Sarcoidosis, Another Disease Associated with Serologic Evidence for Herpes-like Virus Infection. N Engl J Med 1970; 283(10):502-6.

21. Sokoloff L, Bunim JJ. Clinical and Pathological Studies of Joint Involvement in Sarcoidosis. N Engl J Med 1959;260(17):841-7.

22. Welker   L,  Jorres   RA,   Costabel  U,   Magnussen  H.Predictive value of BAL cell differentials in the diagnosis of   interstitial   lung   diseases.   Eur   Respir   J   2004;24(6):1000-6.

23. Zissel G, Prasse A, Muller-Quernheim J. Sarcoidosis-- immunopathogenetic concepts. Semin Respir Crit Care Med 2007; 28(1):3-14.

24. Moller  DR.  Treatment  of  sarcoidosis—from  a  basic science point of view. J Intern Med 2003; 253(1):31–40.

25. Grunewald J, Olerup O, Persson U, Ohrn MB,Wigzell H, Eklund A. T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci USA 1994; 91(11):4965-9.

26. Jones RE, Chatham WW. Update on sarcoidosis. Curr Opin Rheumatol 1999; 11(1):83-7.

27. Eklund A, Grunewald J. The riddle of sarcoidosis: have novel techniques brought any new insights as to the causative agent? J Intern Med 1996; 240(2):59-62.

28. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336(17):1224-34.

29. Epstein WL, James DG. Multiple benign sarcoid of the skin. Arch Dermatol 1999;135:1450.

30. Wahlstrom J, Katchar K, Wigzell H, Olerup O, Eklund A, Grunewald J. Analysis of intracellular cytokines in CD4and CD8lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 2001; 163(1):115–21.

31. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE.Release of tumor necrosis factor by alveolar macrophages of  patients  with  sarcoidosis.  J  Lab  Clin  Med  1990;115(1):36–42.

32. Kennon B, Konnell JM. ACE gene polymorphism and diabetic complications: is there a connection? BioDrugs 2000; 14(2):73–81.

33. Gentilucci  UV,  Picardi  A,  Manfiini  S,  D'Avola  D, Costantino S, Pozzilli P. Granulomatous thyroiditis: an unexpected finding  leading  to  the  diagnosis  of sarcoidosis. Acta Biomed 2004; 75(1):69-73.

34. Spiteri   MA,   Poulter   LW,   Geraint-James   D.   The macrophage in sarcoid granuloma formation. Sarcoidosis 1989; (Suppl 1):12-4.

35. Ota M, Amakawa R, Uehira K, Ito T, Yagi Y, Oshiro A, et  al.  Involvement  of  dendritic  cells  in  sarcoidosis. Thorax 2004; 59(5):408–13.

36. Agostini C, Trentin L, Zambello R, Bulian P, Siviero F, Masciarelli M, et al. CD8 alveolitis in sarcoidosis: incidence,  phenotypic  characteristics,  and  clinical features. Am J Med 1993; 95(5):466-72.

37. Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a TH1/TH17 multisystem disorder. Thorax 2011; 66(2):144-50.

38. Grunewald  J,  Eklund  A.  Role  of  CD4+  T  Cells  in Sarcoidosis. Proc Am Thor Soc 2007; 4(5):461-4.

39. Greene  CM,  Meachery  G,  Taggart  CC,  Rooney  CP, Coakley R, O'Neill SJ, et al. Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol 2000;165(8):4718-24.

40. Larousserie F, Pflanz S, Coulomb-L'Herminé A, Brousse N, Kastelein R, Devergne O. Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 2004; 202(2):164-71.

41. Agostini  C,  Semenzato  G.  Cytokines  in  sarcoidosis.Semin Respir Infect 1998; 13(3):184-96;

42. Ahmadzai H, Cameron B, Chui J, Lloyd A, Wakefield D, Thomas  PS.  Measurement  of  neopterin,  TGF-β1  and ACE in the exhaled breath condensate of patients with sarcoidosis. J Breath Res 2013; 7(4):046003.

43. Agostini   C,   Cabrelle   A,   Calabrese   F,   Bortoli   M, Scquizzato E, Carraro S, et al. Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis.   Am   J   Respir   Crit   Care   Med   2005;172(10):1290-8.

44. Geyer AI, Kraus T, Roberts M, Wisnivesky J, Eber CD, Hiensch R, et al. Plasma level of interferon γ induced protein 10  is  a  marker of sarcoidosis disease activity. Cytokine 2013; 64(1):152-7.

45. Ehrt S, Schnappinger D, Bekiranov S, Drenkow J, Shi S, Gingeras TR, et al. Reprogramming of the macrophage transcriptome in response to interferon-y and Mycobacterium tuberculosis: signaling roles of nitric oxide  synthase-2  and  phagocyte  oxidase.  J  Exp  Med2001; 194(8):1123-40.

46. Agostini C, Trentin L, Facco M, Sancetta R, Cerutti A, Tassinari C, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996; 157(2):910-8.

47. Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P, et al. Enhanced expression of IL-12 associated   with   TH1   cytokine   profiles   in   active pulmonary sarcoidosis. J Immunol 1996; 156(12):4952-60.

48. Walker  C,  Bauer  W,  Braun  RK,  Menz  G,  Braun  P, Schwarz  F,  et  al.  Activated T  cells  and  cytokines  in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994; 150(4):1038-48.

49. Hauber HP, Gholami D, Meyer A, Pforte A. Increased interleukin-13 expression in).patients with sarcoidosis. Thorax 2003; 58(6):519-24.

50. Newman LS. Aetiologies of sarcoidosis. Eur Resp Mon 2005; 32:23–48.

51. Brownell I, Ramirez-Valle F, Sanchez M, Prystowsky S.Evidence for mycobacteria in sarcoidosis. Excellent summary of available literature for and against role of mycobacteria in causation of sarcoidosis. Am J Respir Cell Mol Biol 2011; 45(5):899-905.

52. Dumouchel-Champagne     H,     Charlier-Woerther     C, Boibieux A, Ffrench M, Carret G, Chidiac C, et al. Disseminated nontuberculous infections with Mycobacterium genavense during sarcoidosis. Eur Respir Rev 2009; 18(114):299-301.

53. Pabst  S,  Baumgarten  G,  Stremmel  A,  Lennarz  M, Knüfermann  P,  Gillissen  A,  et  al.  Toll-like  receptor (TLR) 4 polymorphisms are associated with a  chronic course   of   sarcoidosis.   Clin   Exp   Immunol   2006;143(3):420-6.

54. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with    TLR2    in    mediating    optimal    resistance    to Mycobacterium    tuberculosis.    J    Exp    Med    2005;202(12):1715-24.

55. Romics L Jr, Dolganiuc A, Velayudham A, Kodys K, Mandrekar P, Golenbock D, et al. Toll-like receptor 2 mediates inflammatory cytokine induction but not sensitization  for  liver  injury  by  Propioni-  bacterium acnes. J Leukoc Biol 2005; 78(6):1255-64.

56. Yim JJ, Lee HW, Lee HS, Kim YW, Han SK, Shim YS, et al. The association between microsatellite polymorphisms  in  intron  II  of  the  human  Toll-like receptor 2 gene and tuberculosis among Koreans. Genes Immun 2006; 7(2):150-5.

57. Liu  H,  Komai-Koma  M,  Xu  D,  Liew  FY.  Toll-like receptor 2 signaling modulates the functions of  CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006;103(18):7048-53.

58. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203(2):359-70.

59. Mroz RM, Korniluk M, Stasiak-Barmuta A, Ossolinska M, Chyczewska E. Increased levels of Treg cells in bronchoalveolar lavage fluid and induced sputum of patients with active pulmonary sarcoidosis.Eur J Med Res 2009; (14 Suppl 4):165-9.

60. Taflin C, Miyara M, Nochy D, Valeyre D, Naccache JM, Altare F, et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol 2009; 174(2):497-508.

61. Gabrilovich MI, Walrath J, van Lunteren J, Nethery D, Seifu M, Kern JA, et al. Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis. Clin Exp Immunol 2013; 173(3):512-22.

62. Liu DH, Cui W, Chen Q, Huang CM. Can circulating interleukin-18 differentiate between sarcoidosis and idiopathic pulmonary fibrosis? Scand J Clin Lab Invest 2011; 71(7):593-7.

63. Liu  DH,  Yao  YT,  Cui  W,  Chen  K.  The  association between interleukin-18 and pulmonary sarcoidosis: a meta-analysis. Scand J Clin Lab Invest 2010; 70(6):428-32.

64. Mroz RM, Korniluk M, Stasiak-Barmuta A, Chyczewska E. Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J Physiol Pharmacol 2008; (59 Suppl 6):507-13.

65. Antoniou   KM,   Tzouvelekis   A,   Alexandrakis   MG, Tsiligianni I, Tzanakis N, Sfiridaki K, et al. Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid  in  patients  with pulmonary sarcoidosis. J Interferon Cytokine Res 2006; 26(6):400-5.

66. Balamugesh T,  Behera  D,  Bhatnagar A,  Majumdar S.Inflammatory cytokine levels in induced sputum and bronchoalveolar lavage fluid in pulmonary sarcoidosis. Indian J Chest Dis Allied Sci 2006; 48(3):177-81.

67. Kelly  DM,  Greene  CM,  Meachery  G,  O'Mahony  M, Gallagher PM, Taggart CC, et al. Endotoxin up-regulates interleukin-18: potential role for gram-negative colonization in sarcoidosis. Am J Respir Crit Care Med 2005; 172(10):1299-307.

68. Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol 2011; 89(3):383-92.

69. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223:20-38.

70. Kanazawa  N,  Okafuji  I,  Kambe  N,  Nishikomori  R, Nakata-Hizume M, Nagai S, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor- kappaB activation: common genetic etiology with Blau syndrome. Blood 2005; 105(3):1195-7.

71. Wikén   M,   Grunewald  J,   Eklund   A,   Wahlström  J.Highermonocyteexpression of TLR2 and TLR4, and enhancedpro-inflammatorysynergy of TLR2 with NOD2stimulation in sarcoidosis. J Clin Immunol 2009;29(1):78-89.

72. Sakai H, Ito S, Nishikomori R, Takaoka Y, Kawai T, Saito M, et al. A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. Rheumatology 2010;49(1):194-6.

73. Okafuji  I,  Nishikomori  R,  Kanazawa  N,  Kambe  N, Fujisawa A, Yamazaki S, et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 2009; 60(1):242-50.

74. Coto-Segura   P,   Mallo-Garcia   S,   Costa-Romero   M, Arostegui JI, Yague J, Ramos-Polo E, Santos-Juanes J. A sporadic case of early-onset sarcoidosis resembling Blau syndrome due to the recurrent R334W missense mutation on the NOD2 gene. B r J Dermatol 2007; 157(6):1257-9.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.